Trial Profile
A Phase 3 Study to Determine the Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jul 2020
Price :
$35
*
At a glance
- Drugs Rebamipide (Primary)
- Indications Dry eyes
- Focus Registrational; Therapeutic Use
- Sponsors Acucela; Kubota Vision
- 20 Feb 2020 According to an Acucela media release, the company has changed its name to Kubota Vision, effective from 1 Apr 2020.
- 19 Apr 2014 New trial record